Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction

Background Right ventricular (RV) dysfunction predicts adverse outcome in peripartum cardiomyopathy (PPCM). We recently demonstrated beneficial effects associated with the prolactin release inhibitor bromocriptine at different doses when added to standard heart failure therapy in PPCM. Here, we eval...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical research in cardiology 2019-03, Vol.108 (3), p.290-297
Hauptverfasser:	Haghikia, Arash, Schwab, Johannes, Vogel-Claussen, Jens, Berliner, Dominik, Pfeffer, Tobias, König, Tobias, Zwadlo, Carolin, Moulig, Valeska Abou, Franke, Annegret, Schwarzkopf, Marziel, Ehlermann, Philipp, Pfister, Roman, Michels, Guido, Westenfeld, Ralf, Stangl, Verena, Kühl, Uwe, Podewski, Edith, Kindermann, Ingrid, Böhm, Michael, Sliwa, Karen, Hilfiker-Kleiner, Denise, Bauersachs, Johann
Format:	Artikel
Sprache:	eng
Schlagworte:	Bromocriptine Bromocriptine - administration & dosage Cardiology Cardiomyopathies - complications Cardiomyopathies - drug therapy Cardiomyopathies - physiopathology Cardiomyopathy Dose-Response Relationship, Drug Echocardiography Female Follow-Up Studies Heart diseases Heart failure Heart rate Heart Ventricles - diagnostic imaging Heart Ventricles - physiopathology Hormone Antagonists - administration & dosage Humans Magnetic resonance imaging Magnetic Resonance Imaging, Cine Medicine Medicine & Public Health Original Paper Patients Peripartum Period Pregnancy Pregnancy Complications, Cardiovascular Prolactin Prospective Studies Recovery Therapy Treatment Outcome Ventricle Ventricular Dysfunction, Right - drug therapy Ventricular Dysfunction, Right - etiology Ventricular Dysfunction, Right - physiopathology Ventricular Function, Right - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Right ventricular (RV) dysfunction predicts adverse outcome in peripartum cardiomyopathy (PPCM). We recently demonstrated beneficial effects associated with the prolactin release inhibitor bromocriptine at different doses when added to standard heart failure therapy in PPCM. Here, we evaluated for the first time the therapeutic potential of bromocriptine particularly in PPCM patients with RV involvement. Methods In this study, 40 patients with PPCM were included, of whom 24 patients had reduced RV ejection fraction (RVEF
ISSN:	1861-0684 1861-0692 1861-0692
DOI:	10.1007/s00392-018-1355-7